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Prostatic acid phosphatase (PAP) is expressed in nociceptive dorsal root ganglion (DRG) neurons, functions as an ectonucleotidase, and
generates adenosine extracellularly. Here, we found that PAP inhibits noxious thermal sensitivity and sensitization that is associated with
chronic pain through sustained activation of the adenosine A1 receptor (A1R) and phospholipase C-mediated depletion of phosphatidyl-
inositol 4,5-bisphosphate (PIP2 ). In mice, intrathecal injection of PAP reduced PIP2 levels in DRGs, inhibited thermosensation through
TRPV1, and enduringly reduced thermal hyperalgesia and mechanical allodynia caused by inflammation, nerve injury, and pronocicep-
tive receptor activation. This included inhibitory effects on lysophosphatidic acid, purinergic (ATP), bradykinin, and protease-activated
(thrombin) receptors. Conversely, PIP2 levels were significantly elevated in DRGs from Pap
/ mice, and this correlated with enhanced
thermal hyperalgesia and mechanical allodynia in Pap / mice. To directly test the importance of PIP2 in nociception, we intrathecally
injected PIP2 into mice. This transiently (2 h) elevated PIP2 levels in lumbar DRGs and transiently (2 h) enhanced thermosensation.
Additionally, thermal hyperalgesia and mechanical allodynia were enduringly enhanced when PIP2 levels were elevated coincident with
injury/pronociceptive receptor stimulation. Nociceptive sensitization was not affected if PIP2 levels were elevated in the absence of
ongoing pronociceptive receptor stimulation. Together, our data suggest that PIP2 levels in DRGs directly influence thermosensation and
the magnitude of nociceptive sensitization. Moreover, our data suggest there is an underlying “phosphoinositide tone” that can be
manipulated by an adenosine-generating ectonucleotidase. This tone regulates how effectively acute nociceptive insults promote the
transition to chronic pain.
Introduction
Nociceptive neurons in the dorsal root ganglia (DRGs) sense
noxious thermal and mechanical stimuli and can be sensitized
by diverse pronociceptive chemicals (Hucho and Levine, 2007;
Basbaum et al., 2009). Once sensitized, animals often display
long-lasting thermal hyperalgesia and mechanical allodynia—
two common symptoms of chronic pain.
Recently, we found that nociceptive neurons express two
molecularly distinct ectonucleotidases that generate adenosine
extracellularly by dephosphorylating AMP. These ectonucleoti-
dases include the transmembrane (TM) isoform of prostatic acid
phosphatase (PAP) (also known as ACPP) and ecto-5-nucleo-
tidase (NT5E) (also known as CD73) (Zylka et al., 2008; Sowa et
al., 2010). Interestingly, PAP knock-out (Pap/) mice, Nt5e/
mice, and adenosine A1 receptor knock-out (A1R
/) mice all
display enhanced nociceptive responses after inflammation or
nerve injury (Wu et al., 2005; Zylka et al., 2008; Sowa et al., 2010).
These observations suggest that deficiencies in adenosine pro-
duction or A1R signaling enhance nociceptive sensitization; how-
ever, the mechanism underlying these enhanced nociceptive
responses is currently unknown.
The secretory isoform of PAP (S-PAP) also generates adeno-
sine by dephosphorylating AMP (Vihko, 1978; Zylka et al., 2008;
Sowa et al., 2009). When injected intrathecally, S-PAP has long-
lasting (3 d) thermal antinociceptive effects in naive mice as well
as long-lasting antihyperalgesic and antiallodynic effects in sen-
sitized animals (Zylka et al., 2008; Sowa et al., 2009). These
antinociceptive effects were transiently blocked by an A1R antag-
onist and were eliminated in A1R
/ mice, indicating that S-PAP
activates A1R over a sustained time period.
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Adenosine and A1R agonists have antinociceptive effects
when administered acutely to rodents and humans (Eisenach
et al., 2003; Sawynok, 2007). Additionally, acute A1R activation
inhibits neurotransmitter release from nociceptive neurons, voltage-
gated calcium channels, and postsynaptic neurons in spinal cord
(Dolphin et al., 1986; Li and Perl, 1994; Lao et al., 2001). Although
these inhibitory mechanisms may account for some aspects of A1R-
mediated antinociception, inhibition of neurotransmission cannot
readily explain why sustained A1R activation by PAP selectively in-
hibits noxious thermal sensitivity in naive mice without affecting
mechanical sensitivity (Zylka et al., 2008; Sowa et al., 2009). This
selectivity suggests that PAP might regulate thermal nociception by
acting through a specific thermosensory channel.
Indeed, in our present study, we found that PAP acts via A1R
to reduce the levels of phosphatidylinositol 4,5-bisphosphate
(PIP2) in cultured cells and in vivo. In turn, this reduction in PIP2
inhibits thermosensation, in part through the capsaicin and nox-
ious heat receptor TRPV1 (supplemental Fig. S1, available at
www.jneurosci.org as supplemental material) (Caterina et al.,
1997, 2000; Davis et al., 2000). This mechanism is consistent with
several studies showing that PIP2 is required for TRPV1 to func-
tion optimally in vitro (for review, see Rohacs et al., 2008). Prono-
ciceptive G-protein-coupled receptors (GPCRs) also require
PIP2 to signal, suggesting alterations in PIP2 might regulate sen-
sitization through these receptors. Indeed, we found that PAP
inhibited signaling and sensitization through diverse pronoci-
ceptive GPCRs by depleting PIP2 (supplemental Fig. S1, available
at www.jneurosci.org as supplemental material), with PIP2 levels
at the time of stimulation/injury enduringly influencing the level
of nociceptive sensitization. Collectively, our experiments sug-
gest PIP2 plays a central role in nociceptive mechanisms.
Materials and Methods
All procedures and behavioral experiments involving vertebrate animals
were approved by the Institutional Animal Care and Use Committee at
the University of North Carolina at Chapel Hill.
Molecular biology. Full-length expression constructs for mouse TM-PAP
(nucleotides 64-1314 from GenBank accession number NM_207668) and
human TM-PAP (nucleotides 51-1304 from GenBank accession number
BC007460) were generated by reverse transcription (RT)-PCR amplifi-
cation using C57BL/6 mouse trigeminal cDNA or human placental
cDNA (Clontech) as template and Phusion polymerase. The red fluores-
cent protein mCherry was then fused in-frame to the C terminus of all
TM-PAP constructs. Mouse TM-PAP(H12A) was generated by PCR-
based mutagenesis using mouse TM-PAP as template (His12 corre-
sponds to His43 of the mPAP preprotein). This active site mutant was
previously described and lacks catalytic activity (Schneider et al., 1993;
Ostanin et al., 1994). All constructs have a Kosak consensus sequence,
were cloned into pcDNA3.1, and were sequence verified. We obtained
additional constructs from others (see acknowledgments). We con-
firmed that adenosine receptors were expressed in Rat1 fibroblasts by
RT-PCR (A1R primers, 5-CATTGGGCCACAGACCTACT and
5-GGCAGAAGAGGGTGATACA).
Calcium imaging. Cell lines were grown on glass bottom culture dishes
(MatTek; P35G-0-10-C) in DMEM containing 10% fetal bovine serum,
100 U/ml penicillin, and 100 g/ml streptomycin, and transfected with
Lipofectamine Plus (Invitrogen) according to manufacturer’s protocol.
The total amount of DNA per transfection was adjusted to 1 g by adding
pcDNA 3.1. After transfection (18 –24 h), cells were loaded for 1 h at
room temperature with 2 M fura-2 AM (Invitrogen; F-14185) in Hanks
buffered salt solution (HBSS plus calcium and magnesium) assay buffer
(HBSS plus 9 mM HEPES plus 11 mM D-glucose plus 0.1% fatty-acid free
BSA, pH 7.4). Cells were then washed three times with HBSS assay buffer
and sat for at least 30 min before imaging. A Nikon TE2000U microscope
and Sutter DG4 light source were used to image calcium responses (ex-
citation, 340 nm/380 nm; emission, 510 nm). We manually pipetted and
aspirated solutions for all calcium imaging experiments. Cells were stim-
ulated with 1 M capsaicin, 100 nM lysophosphatidic acid (LPA), 1 U/ml
thrombin (Thr), 10 M ATP, or 1 M bradykinin (BK) for 1–5 min,
washed in HBSS assay buffer for 1 min, and then stimulated with 0.006%
SDS to evoke maximal calcium responses for normalization. We did not
use ionomycin to normalize responses because this calcium ionophore
activates calcium-dependent phospholipase C (PLC) enzymes. As a re-
sult, the magnitude of the ionomycin-induced calcium response is also
proportional to PIP2 levels in cells.
Calcium responses were normalized by calculating the area under the
curve during ligand stimulation for each cell, and then dividing by the
maximum SDS-evoked calcium response in each cell. These values were
averaged over all cells for a given condition and then normalized relative
to untransfected cells in the same field of view or relative to control cells
(with the untransfected or control cell response set to 100%).
For experiments with capsaicin, Rat1 fibroblasts were transfected with
TRPV1-green fluorescent protein (GFP) alone or TRPV1-GFP plus var-
ious constructs. The same amount of TRPV1-GFP was used for each
transfection and the total amount of DNA per transfection was adjusted
to 1 g by adding pcDNA 3.1. Cells were stimulated with 1 M capsaicin
(from 100 mM stock in 100% DMSO, dissolved to final concentration in
HBSS assay buffer) for 1 min, followed by a 5 min wash in HBSS assay
buffer, and then stimulation with 0.006% SDS.
For experiments with the PIP2 shuttle, Rat1 fibroblasts were stimu-
lated with 100 nM LPA for 1 min, followed by a 15 min wash with HBSS
assay buffer plus 3 nM PIP2 plus 3 nM Carrier 2 (PIP2 Shuttle kit; Echelon;
P-9045) or HBSS assay buffer plus 3 nM Carrier 2 alone. Cells were then
stimulated with 100 nM LPA again, washed for 1 min with HBSS assay
buffer, and stimulated with 0.006% SDS.
For thapsigargin experiments, HBSS assay buffer lacking calcium and
containing 1 mM EGTA was used to eliminate extracellular calcium. The 10
M thapsigargin was added for 5 min, and the cells were then washed for 2
min with HBSS assay buffer and stimulated with 0.006% SDS. For pertussis
toxin (PTX) experiments, Rat1 fibroblasts were incubated for 18 h with 500
ng/ml PTX before loading with fura-2 AM and stimulation with 100 nM LPA.
For experiments with adenosine receptor antagonists, PLC inhibitor [1-[6-
[[(17)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-
2,5-dione (U73122)], protein kinase C (PKC) inhibitor (staurosporine), or
protein kinase A (PKA) inhibitor [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-
10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3,2,1-kl]
pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, hexyl ester (KT5720)],
cells were incubated with antagonists for 3– 4 h, loaded in the presence of
antagonists/inhibitors with fura-2 AM for 1 h, and then stimulated with
pronociceptive ligands.
Electrophysiology. A HEK293-TRPV1 stable cell line (Kim et al., 2008)
was transfected with TM-PAP-mCherry or TM-PAP(H12A)-mCherry.
Patch-clamp recordings were made from mCherry-expressing cells using
a Multiclamp 700B amplifier and pClamp 9.2 software as described pre-
viously (Campagnola et al., 2008). Heat ramps were generated by ex-
changing bath solution with a preheated solution via a two-to-one port.
Solution was preheated with an in-line heater controlled by a TC-324B
temperature controller modified for high temperature (Warner Instru-
ments). Only one current recording was made per coverslip. The bath
solution consisted of the following (in mM): 140 NaCl, 4 KCl, 2 CaCl2, 2
MgCl2, 10 Na-HEPES, 5 glucose, pH 7.4, mOsm 295–310, and was per-
fused at a rate of 2–3 ml/min by gravity flow. Electrodes were pulled from
borosilicate glass on a Sutter Instrument P-2000 and filled with intracel-
lular solution that contained the following (in mM): 135 KCl, 3 MgATP,
10 HEPES, 0.5 Na2ATP, 1.1 CaCl2, 2 EGTA, 5 glucose, with pH adjusted
to 7.5 with HCl and osmolarity adjusted to 300 mOsm with sucrose. Tip
resistances ranged from 2.5 to 5 M. Series resistance was not compensated;
however, recordings with series resistances 15 M were discarded.
PIP2 quantification. For quantification of PIP2 in vitro, HEK293 cells or
Rat1 fibroblasts were plated onto glass coverslips and transfected with the
construct PLC-PH-GFP along with indicated constructs using Lipo-
fectamine Plus (Invitrogen), according to the manufacturer’s protocol.
Eighteen to 24 h later, the cells were fixed with 4% paraformaldehyde–
PBS. Cells were imaged on a confocal microscope. GFP fluorescence on
the plasma membrane (PM) of cells compared with the cytoplasm was
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quantified using ImageJ by taking cross-sectional averages of pixel inten-
sity at the plasma membrane and dividing by the average of pixel inten-
sity in the cytoplasm.
For quantification of PIP2 in DRGs, age-matched, adult male mice
were injected intrathecally with 5 l of 15% lidocaine plus 50 U/ml hPAP
(250 mU total), 15% lidocaine plus 3 nM Carrier 2 (Echelon; P-9C2), 15%
lidocaine plus 3 nM PIP2 (Echelon; P-9045) plus 3 nM Carrier 2 or 15%
lidocaine alone. Before injection, an equimolar mixture of PIP2 plus
Carrier 2 was incubated for 15 min at room temperature. Lidocaine
causes transient (5–20 min.) paralysis of both hindlimbs, permitting us
to visually determine whether each mouse received a successful intrathe-
cal injection (we only quantified PIP2 levels in mice that showed transient
bilateral paralysis). One day later, mice were killed and lumbar 3 (L3) to
L6 DRGs were dissected bilaterally (n  8 ganglia/sample) and placed in
PBS on ice. For each sample, DRG wet weight was determined, and then
lipids were extracted and quantified using the PI(4,5)P2 Mass ELISA kit
from Echelon (K-4500) following the manufacturer’s protocol. PIP2 lev-
els were normalized by dividing by the wet weight of DRG tissue.
Behavior. Pap /, A1R
/, and Trpv1 / (B6.129X1-Trpv1tm1Jul/J)
mice were backcrossed to C57BL/6 mice for at least 10 generations. For
all other experiments, male, C57BL/6 mice were purchased from The
Jackson Laboratory. Male 2- to 4-month-old mice were used for all be-
havioral studies. All mice were acclimated to testing room, equipment,
and experimenter for 1–3 d before behavioral testing. The experimenter
was blind to genotype and drug treatment during behavioral testing.
Thermal and mechanical sensitivity were measured as described previ-
ously (Zylka et al., 2008). For intrathecal drug delivery, 5 l was injected
into unanesthetized mice using the direct lumbar puncture method
(Fairbanks, 2003). The complete Freund’s adjuvant (CFA) model of in-
flammatory pain and the spared nerve injury (SNI) model of neuropathic
pain were performed as described previously (Shields et al., 2003; Zylka et
al., 2008).
Drugs. Secreted human PAP (S-hPAP) (Sigma-Aldrich; P1774) and heat-
inactivated S-hPAP were prepared as described previously (Zylka et al.,
2008). The 18:1 lysophosphatidic acid (Avanti Polar Lipids; 857130) was
dissolved in 0.9% ethanol and then diluted to final concentrations in either
HBSS assay buffer (calcium imaging) or 0.9% saline (injections). ATP
(Sigma-Aldrich; A26209) was dissolved in either HBSS assay buffer (calcium
imaging) or 0.9% saline (injections). U73122 (Tocris; 1268) was first dis-
solved into DMSO, and then further diluted in 0.9% saline for intrathecal
injection. The PI(4,5)P2 Shuttle PIP kit (Echelon; P-9045) was used to in-
crease PIP2 levels in vivo. PtdIns(4,5)P2 di-C16 was first dissolved into 10%
DMSO in 0.9% saline. Carrier 2 (Histone H1) was dissolved into 0.9% saline.
Before injection, PIP2 and Carrier 2 were mixed in a 1:1 molar ratio and
incubated at room temperature for 15 min. Thrombin (Sigma-Aldrich;
T4648) was first dissolved to 100 U/ml in 0.1% BSA and further diluted in
HBSS assay buffer to final concentrations. BK was dissolved to 1 mM in
DMSO and further diluted in HBSS assay buffer to final concentrations. PTX
(Sigma-Aldrich; P7208) and caffeine (Sigma-Aldrich; C0750) were dissolved
in water. 8-Cyclopentyl-1,3-dimethylxanthine (CPT) (Sigma-Aldrich;
C102), 8-cyclopentyl-1,3-dipropylxanthine (CPX) (Sigma-Aldrich; C101),
7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo
[1,5-c]pyrimidine (SCH 58261) (Sigma-Aldrich; S4568), 8-[4-[((4-cyano-
phenyl)carbamoylmethyl)oxy]phenyl]-1,3-di(n-propyl)xanthine hydrate
(MRS 1754) (Sigma-Aldrich; M6316), 3-propyl-6-ethyl-5-[(ethylthio)car-
bonyl]-2-phenyl-4-propyl-3-pyridine carboxylate (MRS 1523) (Sigma-
Aldrich; M1809), staurosporine (Sigma-Aldrich; S4400), KT5720 (Tocris;
1288), and U73122 (Tocris; 1268) were dissolved in DMSO and further
diluted in HBSS assay buffer to final concentrations.
Results
PAP inhibits activation of TRPV1
We previously found that S-PAP reduced noxious thermal sensi-
tivity by activating A1R for a sustained 3 d time period (Zylka et
al., 2008; Sowa et al., 2009). Since TRPV1 functions as a noxious
heat and capsaicin receptor (Caterina et al., 1997, 2000), we
hypothesized that PAP might reduce thermal sensitivity by inhib-
iting TRPV1. To test this hypothesis, we transfected Rat1 fibro-
blasts with TRPV1 and mouse TM-PAP, and then measured
capsaicin-evoked responses with the calcium indicator fura-2
AM. We observed that both the amplitude and duration of the
capsaicin-evoked calcium response was reduced by 25% in TM-
PAP-transfected cells relative to cells expressing TRPV1 alone
(Fig. 1A). Inhibition was dependent on TM-PAP catalytic activity
because capsaicin-evoked calcium responses were not inhibited
in cells transfected with TM-PAP(H12A), a phosphatase-dead
mutant of TM-PAP (Fig. 1B). Moreover, the A1R-selective antag-
onist CPX blocked the effect of TM-PAP on capsaicin-evoked
signaling (Fig. 1B) (Rat1 cells express A1R) (data not shown).
Last, heat-evoked current density through TRPV1 was reduced in
cells expressing TM-PAP relative to cells expressing catalytically
inactive TM-PAP(H12A) (Fig. 1C). All TM-PAP constructs were
fused to the red fluorescent protein mCherry and were expressed
at similar levels, but only the H12A mutant lacked catalytic activ-
ity (as assessed using enzyme histochemistry) (data not shown).
Collectively, our data suggest that TM-PAP acts via A1R to reduce
capsaicin- and heat-evoked activation of TRPV1.
Next, to determine whether PAP reduced noxious thermal
sensitivity by acting through TRPV1 in vivo, we measured ther-
mal withdrawal latencies in wild-type (WT) and Trpv1/ mice
before and after intrathecal injection of S-hPAP. As previously
observed (Caterina et al., 2000), there were no significant differ-
ences at baseline between WT and Trpv1/ mice when stimu-
lating the hindpaw with radiant heat (Fig. 1D). After S-hPAP
injection, paw withdrawal latency significantly increased (relative
to baseline) at the 30 min time point and remained elevated for
3 d in WT mice (Fig. 1D), reproducing previous results (Zylka et
al., 2008). In contrast, the thermal antinociceptive effect of
S-hPAP was blunted in magnitude ( p  0.001 by two-way
ANOVA; relative to WT) and duration (2 d; relative to baseline)
in Trpv1/ mice (Fig. 1D) (this difference between genotypes
was independently reproduced in Fig. 1F, control paw). S-hPAP
was equally effective at reducing mechanical allodynia in WT and
Trpv1/ mice after CFA-induced inflammation (Fig. 1E, black
dashed line vs red dashed line), ruling out the trivial possibility
that Trpv1/ mice were less sensitive to all antinociceptive ef-
fects of S-hPAP. Although S-hPAP had long-lasting thermal an-
tinociceptive effects in WT mice (Fig. 1F), we were unable to
study the thermal antinociceptive effects of S-hPAP in Trpv1/
mice because Trpv1/ mice did not develop thermal hyperalge-
sia after inflammation (Fig. 1F), as previously found by others
(Caterina et al., 2000; Davis et al., 2000). Together, our cell-based
and in vivo data suggest PAP reduces thermal sensitivity, in part,
by inhibiting TRPV1.
Activation of A1R by TM-PAP depletes PIP2
Our findings raised the question of how sustained, PAP-
dependent activation of A1R inhibited TRPV1 at a mechanistic
level. A1R stimulation inhibits PKA via PTX-sensitive Gi/o-
proteins. In addition, A1R stimulation activates PLC (including
PLC3) via PTX-sensitive G subunits (Murthy and Makhlouf,
1995; Dickenson and Hill, 1998). PLC enzymes then hydrolyze
PIP2 in the membrane to diacylglycerol (DAG) and inositol
triphosphate (IP3). These facts suggested that sustained activa-
tion of A1R might inhibit TRPV1 activity by inhibiting PKA,
activating PKC (via DAG), depleting intracellular calcium stores
(via IP3) or depleting PIP2 (via PLC activation). Although TRPV1
can be modulated by PKC and PKA (Bhave et al., 2002, 2003;
Huang et al., 2006), TM-PAP did not inhibit TRPV1 through
PKC or PKA pathways (supplemental Fig. S2A,B, available at
www.jneurosci.org as supplemental material). Nor did TM-PAP
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deplete intracellular calcium stores (supplemental Fig. S2C, avail-
able at www.jneurosci.org as supplemental material).
TRPV1 is also modulated by PIP2 (Prescott and Julius, 2003;
Liu et al., 2005; Stein et al., 2006; Lishko et al., 2007; Lukacs et al.,
2007; Klein et al., 2008; Rohacs et al., 2008; Yao and Qin, 2009).
At high capsaicin concentrations (1 M) and in the presence of
extracellular calcium, PIP2 is required for TRPV1 channel activ-
ity, whereas depletion of PIP2 desensitizes the channel. This re-
quirement for PIP2 suggested TM-PAP might inhibit TRPV1 by
reducing cellular levels of PIP2 through sustained A1R activation.
To test this possibility, we quantified the levels of PIP2 in cells
using the biosensor PLC-PH-GFP (Várnai and Balla, 1998).
When PIP2 levels are high, PLC-PH-GFP is primarily localized
to the PM. When PIP2 levels are reduced, PLC-PH-GFP trans-
locates from the membrane to the cytosol. This translocation can
be quantified by measuring the GFP signal intensity on the PM
relative to the cytosol (expressed as the ratio PM/cytosol). We
used HEK293 cells for these experiments because this biosensor
was difficult to visualize in Rat1 fibroblasts (although we repro-
duced our key finding in Rat1 cells) (supplemental Fig. S3, avail-
able at www.jneurosci.org as supplemental material).
In HEK293 cells expressing only PLC-PH-GFP, the majority
of the GFP signal was in the PM, giving a PM/cytosol ratio of
3.43  0.35 (Fig. 2A,E). In contrast, PLC-PH-GFP was redis-
tributed to the cytosol in cells cotransfected with TM-PAP or
PLC3 (PM/cytosol ratio of 1.60  0.06 and 1.70  0.9, respec-
tively) (Fig. 2B,E). This finding suggested TM-PAP and PLC3
depleted PIP2 to a similar extent when expressed for an extended
(	24 h) time period. Importantly, the A1R antagonist CPX and
the PLC inhibitor U73122 blocked the TM-PAP-mediated redis-
tribution of PLC-PH-GFP to the cytosol (Fig. 2C,E), suggesting
that TM-PAP depleted PIP2 by acting through A1R and PLC.
Additionally, the TM-PAP- and PLC3-mediated redistribution
of PLC-PH-GFP was blocked by overexpressing phosphatidy-
linositol-4-phosphate-5-kinase (PIPK) (Fig. 2D,E). PIPK in-
creases PIP2 levels in transfected cells (Lin et al., 2005; Milosevic
et al., 2005), suggesting TM-PAP and PLC3 altered PLC-PH-
GFP membrane localization by depleting PIP2.
TM-PAP reduces TRPV1 activity by depleting PIP2
Next, we genetically manipulated PIP2 levels to determine
whether increasing or decreasing PIP2 affected capsaicin-evoked
calcium responses. Both TM-PAP and PLC3 deplete PIP2 to a
similar extent (Fig. 2E), but only PLC3 hydrolyzes PIP2 directly.
Likewise, both TM-PAP and PLC3 reduced capsaicin-evoked
calcium responses to a similar extent (Fig. 2F), suggesting indi-
rect or direct depletion of PIP2 was sufficient to reduce TRPV1
activity. Conversely, increasing PIP2 levels by overexpressing
PIPK (which regenerates PIP2) blocked TM-PAP and PLC3
from inhibiting capsaicin-evoked calcium responses (Fig. 2F).
These findings suggested signaling through TRPV1 was reduced
as a direct result of PIP2 depletion, consistent with the findings of
Figure 1. PAP reduces activity of the capsaicin and noxious heat receptor TRPV1. A, Capsaicin (1 M)-evoked calcium responses in Rat1 fibroblasts expressing TRPV1 alone or with TM-PAP. The
340/380 ratio is directly proportional to calcium concentration; n  80 cells per condition. B, Normalized capsaicin-evoked calcium responses in Rat1 fibroblasts transfected with the indicated
constructs. Where indicated, cells were incubated with CPX (5 M) for 3 h before stimulation; n  40 – 60 cells per condition; t tests relative to TRPV1 only condition. C, Noxious heat-evoked currents
and current density in HEK293-TRPV1 stable cells transfected with TM-PAP or the catalytically inactive H12A mutant; n  20 cells per condition. D, The hindpaws of WT (black) and Trpv1 / mice
(red) were tested for noxious thermal sensitivity before [baseline (BL)] and after intrathecal injection of S-hPAP (250 mU). Paired t tests were used to compare responses within each genotype to BL
(black asterisks) and between genotypes (red asterisks); n  10 mice per genotype. D, Inset, Detailed time course to determine onset of antinociception. E, F, Mechanical (E) and thermal (F )
sensitivity of WT and Trpv1 / mice before (BL) and after injection of CFA into one hindpaw. One day later, the indicated mice were injected intrathecally with S-hPAP (250 mU) or heat-inactivated
S-hPAP (0 mU). CFA-injected and noninjected (control) hindpaws were tested. Paired t tests were used to compare responses at each time point between WT mice and Trpv1 / mice injected with
S-hPAP (red asterisks); n  8 mice per group; paired t test, *p  0.05, **p  0.005, ***p  0.0005. All data are presented as means  SEM.
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others using cultured cells (Liu et al.,
2005; Stein et al., 2006; Lishko et al., 2007;
Lukacs et al., 2007; Klein et al., 2008; Ro-
hacs et al., 2008; Yao and Qin, 2009). In
addition, TM-PAP did not affect the
capsaicin-evoked calcium response in
cells expressing TRPV142(777-820)
(data not shown), a TRPV1 mutant that is
missing a putative PIP2 binding domain
(Prescott and Julius, 2003; Kwon et al.,
2007; Kim et al., 2008). Together, these
data show that TM-PAP reduces TRPV1
activity in vitro through sustained activa-
tion of A1R and subsequent depletion of
PIP2.
PAP regulates PIP2 levels in vivo
Since PAP regulated PIP2 levels in cul-
tured cells, we hypothesized PAP might
also regulate PIP2 levels in vivo. To test
this hypothesis, we measured PIP2 levels
in L3–L6 DRGs from WT mice that were
injected (intrathecally) with vehicle or
S-hPAP. We collected DRGs 1 d after in-
jections because S-hPAP has maximal
A1R-dependent antinociceptive effects at
this time (Zylka et al., 2008). Injection of
S-hPAP significantly reduced PIP2 levels
by 40  9% (Fig. 3A), and this reduction
was dependent on A1R activation [as evi-
denced by the observation that PIP2 levels
in L3–L6 DRGs were not significantly dif-
ferent in A1R
/ mice injected (intrathe-
cally) 1 d earlier with 250 mU of S-hPAP
(250 mU) relative to heat-inactivated
S-hPAP (0 mU); 159.6  23.5 pmol/mg
DRG vs 174.4  28.0 pmol/mg DRG, respectively; n  4 mice per
condition]. Conversely, PIP2 levels were elevated by 89  23% in
DRGs from Pap/ mice (Fig. 3A). Together, these data suggest
PIP2 levels are inversely related to the amount of PAP ectonucle-
otidase activity and A1R stimulation.
Since our cell-based data suggested that PAP depleted PIP2 by
activating PLC, we next evaluated whether the thermal antinoci-
ceptive effect of S-hPAP could be blocked using the PLC inhibitor
U73122. This inhibitor was previously injected intrathecally (at
5.4 nmol) to block PLC activation by a -opioid receptor ligand
(Narita et al., 2000). Indeed, intrathecal injection of U73122 at
the same dose transiently and completely blocked the thermal
antinociceptive effect of S-hPAP, providing evidence that
S-hPAP acted through PLC to reduce thermal sensitivity in vivo
(Fig. 3B,C). Importantly, the 5.4 nmol dose had no effect on
thermal sensitivity when injected alone (Fig. 3B,C) (Narita et al.,
2000). However, a higher U73122 dose (12.5 nmol) transiently
enhanced thermal sensitivity (supplemental Fig. S4, available at
www.jneurosci.org as supplemental material). Since strong PLC
inhibition would be predicted to elevate PIP2 levels, this latter
result suggests that the PLC/PIP2 pathway tonically modulates
thermal thresholds.
To directly assess whether S-hPAP reduced thermal sensitivity
by depleting PIP2, we transiently replenished PIP2 in lumbar
DRGs using a PIP2 shuttle (Ozaki et al., 2000). We found that
injection (intrathecally) of PIP2 (complexed with carrier) tran-
siently (2 h) elevated PIP2 levels well above normal levels in lum-
bar DRGs (Fig. 3D), whereas injection of carrier alone (the
control) had no effect (based on the observation that PIP2 levels
in L3–L6 DRGs were not significantly different in WT mice rela-
tive to WT mice injected intrathecally with Car; 112.0  14.6
pmol/mg DRG vs 102.5  10.5 pmol/mg DRG, respectively; n 
4 mice per condition). Strikingly, intrathecal injection of PIP2
(complexed with carrier) also transiently (2 h) reversed S-hPAP-
mediated thermal antinociception, whereas carrier alone had
no effect (Fig. 3E,F). The fact that behavior was significantly
altered only during the time at which PIP2 was significantly ele-
vated makes it unlikely these effects on thermal sensitivity were a
coincidence. Instead, these results strongly suggest that PAP in-
hibits thermal sensitivity as a direct result of PIP2 depletion.
Moreover, control animals injected with PIP2 displayed transient
thermal hyperalgesia, suggesting thermal sensitivity can be en-
hanced when PIP2 levels are elevated above normal levels. The
magnitude of this effect on thermal sensitivity in control animals
was smaller (2.6 s) than in animals that were injected with
S-hPAP and PIP2 (4.0 s). This argues that PIP2 replenishment was
sufficient to block the thermal antinociceptive effect of S-hPAP
independent of how PIP2 affects thermal sensitivity in control
animals.
Together, our data strongly support a mechanism (Fig. 3G) in
which (1) TM- and S-PAP function as ectonucleotidases that
generate adenosine. Adenosine then stimulates (2) A1R in a sus-
tained fashion, followed by (3) PLC activation and (4) PIP2 hy-
drolysis. (5) Sustained reductions in PIP2 levels decreased TRPV1
Figure 2. TM-PAP reduces capsaicin-evoked calcium responses by decreasing PIP2. A–D, Subcellular localization of the PIP2
biosensor PLC-PH-EGFP (PLC-PH) in HEK293 cells, imaged by confocal microscopy. PLC-PH alone (A), cotransfected with
TM-PAP (B), cotransfected with TM-PAP and incubated with 5 M CPX for 3 h before fixation (C), and cotransfected with TM-PAP
and PIPK (D). Scale bar, 10 m. E, Quantification of PLC-PH subcellular localization after cotransfection with the indicated
constructs or after incubation with CPX. Fluorescence values in the PM and cytosol were quantified from cell cross-sections using
ImageJ and expressed as a ratio; n  30 –70 cells per condition. F, Normalized capsaicin (1 M)-evoked calcium responses in Rat1
fibroblasts transfected with the indicated constructs; n  40 –100 cells per condition; t tests were used to compare PLC-PH-
transfected cells to cotransfected cells (E) and TRPV1-transfected cells to cotransfected cells (F ). ***p  0.0005. All data are
presented as means  SEM.
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activity and decreased noxious thermal sensitivity. In addition,
our data suggest PIP2 levels are regulated by tonic ectonucleo-
tidase-dependent adenosine production and A1R activation.
PAP inhibits pronociceptive LPA receptor signaling by
reducing PIP2 levels
Diverse chemicals are released after injury and inflammation and
sensitize nociceptive neurons, in many cases, by activating
pronociceptive GPCRs (Hucho and Levine, 2007; Basbaum et al.,
2009). Since many pronociceptive receptors signal through PLC
(and hence require PIP2 for signaling), we hypothesized that PAP
might reduce signaling through pronociceptive receptors via sus-
tained activation of A1R and PIP2 depletion. Such a mechanism
could have important physiological implications because re-
duced signaling through pronociceptive receptors would be pre-
dicted to reduce nociceptive sensitization, a key symptom of
chronic pain. LPA is a pronociceptive ligand that sensitizes noci-
ceptive neurons, causes long-lasting (7 d) sensitization in vivo
(including thermal hyperalgesia and mechanical allodynia), and
is implicated in neuropathic pain mechanisms (Elmes et al., 2004;
Inoue et al., 2004; Park and Vasko, 2005). In addition, LPA re-
ceptors are coupled to Gq/11-proteins and signal through PLC in
many cell types, including Rat1 fibroblasts (which endogenously
express LPA receptors) (Mills and Moolenaar, 2003; Kelley et al.,
2006).
Using Rat1 fibroblasts, we found that the amplitude and du-
ration of LPA-evoked calcium responses were significantly re-
duced in cells expressing TM-PAP relative to untransfected cells
in the same field of view (Fig. 4A,D). This “PAP effect” was
species-conserved as cells transfected with TM-hPAP (human
TM-PAP) were also less responsive to LPA stimulation (Fig.
4B,D). In contrast, the LPA-evoked calcium response was not
reduced in cells transfected with the catalytically inactive TM-
PAP(H12A) mutant (Fig. 4C,D).
To determine whether TM-PAP inhibited LPA-evoked signal-
ing by generating adenosine and activating A1R, we assessed
whether PTX (an inhibitor of Gi/o-coupled receptors) or aden-
osine receptor antagonists could block the effect of TM-PAP on
LPA-evoked signaling. We found that PTX completely blocked
the PAP effect, as evidenced by no significant differences between
Figure 3. Manipulation of PIP2 levels in vivo. A, PIP2 levels in L3–L6 DRGs were quantified in WT mice, Pap
/ mice, or WT mice injected (intrathecally) 1 d earlier with 250 mU of S-hPAP. Values
were compared with WT by paired t test; n  3 mice per condition. B, C, The hindpaws of WT mice were tested for noxious thermal sensitivity before [baseline (BL)] and after intrathecal injection
of S-hPAP (250 mU) or saline. Two days later, the indicated mice were injected intrathecally with either U73122 (5.4 nmol) or vehicle (V) and thermal sensitivity was measured every hour for the first
7 h as well as for the next 2 d. Data in C are from the boxed area in B. Mice injected with U73122 were compared with vehicle-injected mice at each time point by paired t test; n  8 mice per group.
D, PIP2 in L3–L6 DRGs was quantified in WT mice at the given time points after intrathecal injection with PIP2 (3 nmol) plus carrier. Mice from later time points were compared with time 0 values by
paired t test; n  4 mice per condition. E, F, The hindpaws of WT mice were tested for noxious thermal sensitivity before (BL) and after intrathecal injection of S-hPAP (250 mU) or saline. Two days
later, the indicated mice were injected intrathecally with carrier (Car) or PIP2 (3 nmol) plus carrier, and then thermal sensitivity was measured every hour for the first 6 h after injection as well as for
the next 2 d. Data in F are from the boxed area in E. Mice injected with PIP2 after S-hPAP were compared with vehicle-injected mice at each time point by paired t test. G, Model showing how PAP
interferes with TRPV1 channel activity (see text for details). *p  0.05, **p  0.005, ***p  0.0005. All data are presented as means  SEM.
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untransfected cells and TM-PAP plus
PTX-treated cells (Fig. 4D). Additionally,
the PAP effect was blocked by the A1/A2B
adenosine receptor antagonist caffeine
(Caff) and by two different A1R-selective
antagonists: CPT and CPX (Fig. 4D). In
contrast, selective antagonists of all other
adenosine receptors (A2AR, SCH 58261;
A2BR, MRS 1754; A3R, MRS 1523) did not
block the PAP effect (data not shown).
Next, we evaluated whether increasing
or decreasing PIP2 affected LPA-evoked
calcium responses in our cell-based assay.
We found that both TM-PAP and PLC3
reduced LPA-evoked calcium responses
to a similar extent (Fig. 4D), suggesting
indirect or direct depletion of PIP2 was
sufficient to reduce signaling. This is con-
sistent with a previous study showing that
LPA-evoked Ca 2
 responses were re-
duced to baseline levels when PIP2 was
depleted using an inducible PIP2 phos-
phatase (Várnai et al., 2006). Conversely,
increasing PIP2 levels by overexpressing
PIPK blocked the TM-PAP- and PLC3-
mediated reduction in LPA-evoked cal-
cium responses (Fig. 4D). Moreover,
restoring PIP2 levels with the PIP2 shuttle
blocked the inhibitory effect of TM-PAP
(supplemental Fig. S5, available at www.
jneurosci.org as supplemental material).
These experiments provide complemen-
tary support that TM-PAP inhibits LPA
receptor signaling as a direct result of PIP2
depletion. The inhibitory effect of TM-
PAP was also blocked with the PLC inhib-
itor U73122 (Fig. 4D), further indicating
that TM-PAP acts via PLC to deplete PIP2.
As expected, the magnitude of the LPA-
evoked Ca 2
 influx was smaller in all cells
when PLC was inhibited. Last, TM-PAP
did not reduce LPA signaling by acting
through other pathways that are down-
stream of A1R, including Gi/o-mediated inhibition of PKA or
DAG-mediated PKC activation (data not shown).
TM-PAP reduces signaling through several
pronociceptive GPCRs
Since many pronociceptive receptors are Gq/11-coupled and sig-
nal via PLC, we hypothesized that TM-PAP might reduce signaling
through additional pronociceptive receptors, including purinergic
receptors (using the ligand ATP), protease-activated receptors (us-
ing the ligand Thr), and BK receptors. Importantly, activation of
these receptors evokes transient calcium responses in Rat1 cells
and causes nociceptive sensitization in vivo (Kelley et al., 2006;
Wang et al., 2006; Burnstock, 2007; Sawynok, 2007; Dale and
Vergnolle, 2008). Strikingly, calcium responses induced by all three
ligands were reduced in TM-PAP-transfected cells relative to un-
transfected cells, and these reductions were blocked by the A1R an-
tagonist CPX and by overexpressing PIPK (Fig. 4E).
Collectively, our data further support a mechanism (Fig. 4F)
in which (1) PAP functions as an ectonucleotidase to generate
adenosine over a sustained time period. (2) Adenosine then stim-
ulates A1R followed by (3) PLC activation and (4) PIP2 hydro-
lysis. With less PIP2 available for (5) Gq/11/PLC-mediated
receptor signaling, less IP3 (and DAG) is generated after re-
ceptor stimulation, resulting in smaller pronociceptive ligand-
evoked calcium responses.
PAP enduringly blocks LPA- and ATP-induced hyperalgesia
and allodynia
Since PAP reduced pronociceptive receptor signaling in Rat1 cells
by depleting PIP2, we hypothesized that PAP might also reduce
signaling through pronociceptive receptors in vivo. To test this
possibility, we took advantage of the fact that both LPA and ATP
produce long-lasting (7 d) thermal hyperalgesia and mechani-
cal allodynia when injected intrathecally (Inoue et al., 2004; Na-
kagawa et al., 2007). This is longer than the 3 d antihyperalgesic
and antiallodynic effects of S-hPAP (Zylka et al., 2008). Thus, by
injecting S-hPAP 1 d before ATP or LPA, we could ascertain
whether S-hPAP reduced initiation of LPA- or ATP-evoked sig-
naling by quantifying hyperalgesia and allodynia on days 4 and 8
(i.e., after the 3 d antinociceptive effects of PAP wore off).
Figure 4. TM-PAP reduces pronociceptive ligand-evoked calcium responses in Rat1 fibroblasts through activation of A1R. A–C,
LPA (100 nM)-evoked calcium responses in untransfected cells and in cells transfected with the indicated constructs; n  15 cells
per condition. D, LPA-evoked calcium responses in cells expressing the indicated constructs and after incubation with PTX (500
ng/ml), caffeine (Caff) (1 mM), CPT (500 nM), CPX (5 M), or U73122 (5 M). Incubation time was 18 h for PTX and 3 h for all other
compounds. Responses normalized to untransfected cells (Untrans); n  70 –100 cells per condition. E, Normalized calcium
responses in Rat1 fibroblasts stimulated with ATP (10 M), Thr (1 U/ml), or BK (1 M). The indicated cells were incubated with CPX
(5 M) for 3 h before stimulation; n  70 –110 cells per condition. F, Model showing how PAP inhibits pronociceptive receptor
signaling (see text for details). For A–C, two-way ANOVA was used to compare transfected and untransfected cells ( p values
indicated on graphs). For D and E, t tests were used to compare untransfected cells to transfected cells. ***p  0.0005. All data are
presented as means  SEM.
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First, we measured baseline (BL) thermal and mechanical sen-
sitivity in two groups of WT mice. Next, we injected S-hPAP
(intrathecally) into one of the groups and heat-inactivated S-hPAP
(control; catalytically dead) into the other group (Fig. 5) (a third
group of S-hPAP-injected mice from a different experiment is
shown, to provide a visual reference for how S-hPAP typically
affects naive mice). One day later, S-hPAP increased paw with-
drawal latency to the noxious thermal stimulus but had no effect
on mechanical sensitivity, whereas inactive S-hPAP had no ef-
fects on thermal or mechanical sensitivity (Fig. 5). These results
were expected (Zylka et al., 2008) and confirmed that mice re-
ceived an active or inactive dose of S-hPAP. After taking these
measurements, we injected (intrathecally) either 5 nmol of LPA
(Fig. 5A,B) or 100 nmol of ATP (Fig. 5C,D). These doses produce
maximal sensitization in animals (Inoue et al., 2004; Nakagawa et
al., 2007). Both pronociceptive compounds produced long-
lasting thermal hyperalgesia and mechanical allodynia in the con-
trol (inactive S-hPAP-injected) mice. In contrast, mice injected
with S-hPAP and then LPA/ATP were significantly different from
controls at all times after LPA/ATP injections and did not develop
thermal hyperalgesia or mechanical allodynia, as evidenced by
latencies and thresholds that were at or near baseline levels on
days 4 and 8. These data suggest that PAP, an enzyme that reduces
PIP2 levels in vivo (Fig. 3A), blocked physiologically relevant sig-
naling and sensitization through two distinct pronociceptive re-
ceptors. Conversely, thermal hyperalgesia and mechanical
allodynia were significantly and enduringly enhanced after LPA
or ATP injection in Pap/ mice (Fig. 6)—that is, mice that have
elevated levels of PIP2 in lumbar DRGs (Fig. 3A).
PAP preemptively inhibits sensitization
caused by inflammation and
nerve injury
Although LPA and ATP produce long-
lasting sensitization in vivo, injection of
these chemicals may not fully model the
sensitization and pathology that is associ-
ated with chronic pain conditions. To de-
termine whether reducing PIP2 levels with
S-hPAP had a more generalized effect on
the signals that initiate pain sensitization,
we tested S-hPAP in the CFA model of
inflammatory pain and in the SNI model
of neuropathic pain. Strikingly, intrathe-
cal injection of S-hPAP before CFA-
induced inflammation nearly eliminated
thermal hyperalgesia and significantly re-
duced mechanical allodynia for the dura-
tion of the experiment compared with
controls injected with inactive S-hPAP
(Fig. 7A,B). These preemptive antinoci-
ceptive effects of S-hPAP were dependent
on A1R activation (supplemental Fig. S6,
available at www.jneurosci.org as supple-
mental material). In addition, intrathecal
injection of S-hPAP before nerve injury
eliminated thermal hyperalgesia and sig-
nificantly reduced mechanical allodynia
for the duration of the experiment com-
pared with mice injected with inactive
S-hPAP (Fig. 7C,D). Collectively, these
findings indicate that S-hPAP enduringly
blocks sensitization in two chronic pain
models when injected before inflammation/injury.
Direct elevation of PIP2 in DRGs enhances
nociceptive sensitization
Since PIP2 levels in DRGs were indirectly elevated and sensitiza-
tion was enhanced in Pap/ mice [data above and in the study
by Zylka et al. (2008)], we next sought to determine whether
direct elevation of PIP2 in DRGs could enhance sensitization. To
accomplish this, we coinjected (intrathecally) WT mice with LPA
plus Car (the control) or LPA plus PIP2 plus Car, and then mea-
sured noxious thermal and mechanical sensitivity for several
days. Importantly, there is a critical window of 3 h over which
LPA (injected intrathecally) signals to produce nociceptive sen-
sitization in mice (Ma et al., 2009). Since PIP2 levels are only
elevated in DRGs for 2 h after injection (Fig. 3D), these coinjec-
tion experiments allowed us to elevate PIP2 levels only when LPA
receptors were active in vivo. Strikingly, when PIP2 levels were
elevated coincident with LPA receptor activation, thermal hyper-
algesia and mechanical allodynia were significantly and repro-
ducibly enhanced for the duration of the experiment (Fig. 8A,B).
In contrast, injection of Car alone or PIP2 plus Car in the absence
of a pronociceptive stimulus had no long-term effects on thermal
or mechanical sensitivity (Fig. 8C,D). And injection of Car alone
or PIP2 plus Car did not sensitize mice when injected 3 d after
LPA was injected (i.e., well past the 3 h critical window for LPA
receptor signaling) (Fig. 8E,F). In this same experiment, PIP2
plus Car (but not Car alone) caused a transient (2 h) enhance-
ment in thermal sensitivity (data not shown), thus reproduc-
ing our findings above (Fig. 3 E, F ) and confirming that these
PIP2 injections were successful and had the capacity to affect
Figure 5. Secretory PAP inhibits pronociceptive receptor signaling in vivo. A–D, The hindpaws of WT mice (n  10 per group)
were tested for noxious thermal and mechanical sensitivity before [baseline (BL)] and after intrathecal injection of S-hPAP (250
mU) or heat-inactivated S-hPAP (0 mU). One day later, mice were injected intrathecally with 5 nmol of LPA (A, B) or 100 nmol of
ATP (C, D). Paired t tests were used to compare responses at each time point between mice injected with S-hPAP plus LPA to mice
injected with inactive S-hPAP plus LPA. The S-hPAP data (open squares) shown in A–D are from a different experiment with WT
mice and are plotted here to provide a visual, not statistical, reference for comparison. **p  0.005, ***p  0.0005. All data are
presented as means  SEM.
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behavior. Together, these experiments
strongly argue that PIP2 levels must be
elevated in DRGs at the time of prono-
ciceptive receptor activation to enhance
thermal and mechanical sensitization.
Last, we sought to determine whether
direct elevation of PIP2 could enhance
thermal and mechanical sensitization
caused by CFA. For this experiment, all
mice were injected intrathecally with Car
or PIP2 plus Car immediately before in-
jecting CFA into one hindpaw. CFA sen-
sitizes nociceptors through the release of
an “inflammatory soup” composed of di-
verse pronociceptive ligands (Basbaum et
al., 2009). Since this soup could activate
pronociceptive receptors for an extended
period of time (and since PIP2 is only ele-
vated for 2 h after a single injection), we
reinjected (intrathecally) all mice 2 h later
with PIP2 plus Car (or Car alone). This
ensured that PIP2 levels remained ele-
vated while CFA “initiated” sensitization.
Strikingly, CFA-induced thermal hyperal-
gesia and mechanical allodynia were sig-
nificantly enhanced for the duration of
the experiment when PIP2 levels were
transiently elevated (Fig. 8G,H) [compare
the inflamed paw of PIP2 plus Car-
injected mice to the inflamed paw of Car
alone (control) mice]. In contrast, ther-
mal and mechanical responses were not
altered in the contralateral (uninflamed)
paws of mice injected with PIP2 plus Car
(Fig. 8G,H), further demonstrating that
acute elevation of PIP2 does not sensitize
mice in the absence of a pronociceptive
stimulus.
Discussion
In our effort to determine how PAP regu-
lated nociception at a mechanistic level, we
found that sustained A1R activation re-
duced the levels of PIP2 in cells and in DRGs.
This reduction in PIP2 reduced noxious
thermal sensitivity, in part through inhibi-
tion of TRPV1. And this reduction in
PIP2 enduringly reduced nociceptive




Numerous studies found that TRPV1 can
be modulated by PIP2 in vitro (for review,
see Rohacs et al., 2008). At low capsaicin
concentrations and in the absence of ex-
tracellular calcium, PIP2 partially inhibits
TRPV1 (Prescott and Julius, 2003). In
contrast, at high capsaicin concentrations
and in the presence of extracellular calcium, PIP2 is required for
TRPV1 activity (Liu et al., 2005; Stein et al., 2006; Lishko et al.,
2007; Lukacs et al., 2007; Klein et al., 2008; Yao and Qin, 2009).
These contrasting in vitro results made it difficult to predict how
alterations in the levels of PIP2 might affect thermosensation in
animals. In our present study, we found that PAP inhibited
TRPV1 in cultured cells through sustained A1R activation and
Figure 6. Pap / mice show enhanced LPA- and ATP-induced thermal hyperalgesia and mechanical allodynia. A–D, The
hindpaws of WT and Pap / mice were tested for noxious thermal and mechanical sensitivity before [baseline (BL)] and after
intrathecal injection of LPA (5 nmol) (A, B) or ATP (100 nmol) (C, D); n  10 mice per genotype. Pap / mice developed
significantly greater thermal hyperalgesia ( p  0.0001 by two-way ANOVA) and mechanical allodynia ( p  0.0001 by two-way
ANOVA) in response to intrathecal LPA or ATP. Post hoc paired t tests were used to compare responses at each time point between
genotypes. *p  0.05, **p  0.005, ***p  0.0005. All data are presented as means  SEM.
Figure 7. Secretory PAP partially blocks the initiation of inflammatory and neuropathic pain. A–D, The hindpaws of WT mice
(n10 per group) were tested for noxious thermal and mechanical sensitivity before [baseline (BL)] and after intrathecal injection
of S-hPAP (250 mU) or heat-inactivated S-hPAP (0 mU). One day later, CFA was injected into one hindpaw (CFA arrowhead) (A, B)
or peripheral nerves were injured using the SNI model of neuropathic pain (Injure arrowhead) (C, D). Paired t tests were used to
compare responses at each time point between mice injected with S-hPAP (open square; injured paw) and those injected with
inactive hPAP (open circles; injured paw). *p  0.05, **p  0.005, ***p  0.0005. All data are presented as means  SEM.
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PLC-mediated PIP2 depletion. Likewise, PAP inhibited ther-
mosensation in mice through A1R activation (Zylka et al., 2008),
PLC activation (Fig. 3B,C), and A1R-dependent PIP2 depletion
(Fig. 3A and data above). Moreover, the inhibitory effect of PAP
on thermosensation was partially dependent on TRPV1 activa-
tion (Fig. 1D). Conversely, thermosensation was modestly en-
hanced when PIP2 levels were elevated in vivo (Fig. 3E,F).
Together, our findings suggest that PIP2 facilitates thermosensa-
tion in vivo through TRPV1-dependent and independent mech-
anisms. Our findings are consistent with a study showing that
TRPV1-dependent thermosensation was enhanced through in-
teractions with PIRT, a PIP2-binding protein (Kim et al., 2008).
Pronociceptive GPCR activation can sensitize TRPV1 via
PKC/PLC (Bhave et al., 2003; Huang et al., 2006). Since A1R is
also coupled to PLC (Murthy and Makhlouf, 1995; Jacobson and
Gao, 2006), this raises the question of why PAP inhibits TRPV1
following A1R activation, as we observed, instead of sensitizing
TRPV1? This likely reflects differences in how pronociceptive
GPCRs and A1R couple to downstream signaling pathways.
Pronociceptive receptors, including LPA receptors, are coupled
to PLC isoforms via Gq/11- and G-proteins. Stimulation of
these receptors evokes transient PKC activation and large PLC-
dependent calcium responses that desensitize rapidly (Mills and
Moolenaar, 2003; Kelley et al., 2006). In contrast, A1R is coupled
to PLC isoforms exclusively via G-proteins and A1R does not
desensitize, at least when activated by ectonucleotidase-
generated adenosine. Specifically, we found that A1R does not
desensitize when activated for a sustained 3 d time period by PAP
(Zylka et al., 2008; Sowa et al., 2009) or on repeated injection of
S-hPAP (data not shown). And importantly, the PLC inhibitor
U73122 transiently inhibited PAP antinociception (Fig. 3B,C),
arguing that PLC is active over this 3 d period. These data suggest
that ectonucleotidase-dependent activation of A1R is sufficient to
deplete PIP2 and inhibit TRPV1 but is not sufficient to activate
PKC, sensitize TRPV1, or detectably elevate calcium levels. In-
deed, we found that PAP did not inhibit TRPV1 through PKC
(supplemental Fig. S2A, available at www.jneurosci.org as sup-
plemental material) nor did PAP reduce intracellular (IP3-
sensitive) calcium stores (supplemental Fig. S2C, available at
www.jneurosci.org as supplemental material). And acute stimu-
lation with the A1R agonist N
6-cyclopentyladenosine (300 nM)
did not evoke Ca 2
 influx in cultured small-diameter DRG neu-
rons from adult mice (E. McCoy and M. J. Zylka, unpublished
data).
We found that most of the thermal antinociceptive effects of
PAP were lost in Trpv1/ mice, whereas the mechanical antino-
ciceptive effects of PAP were preserved (Fig. 1D–F). This disso-
ciation suggests that most of the thermal antinociceptive effects
of PAP were mediated through TRPV1, whereas the remaining
thermal and mechanical antinociceptive effects of PAP were
likely mediated by other PIP2-sensitive channels or proteins. De-
pletion of PIP2 generally reduces ion channel activity, including
KCNQ, P2X4, and N-type calcium channels (Gamper et al., 2004;
Suh and Hille, 2005; Bernier et al., 2008), all of which could affect
nociception (Basbaum et al., 2009). In addition, PIP2 depletion
inhibits synaptic vesicle exocytosis (Di Paolo and De Camilli,
2006). Additional studies will be needed to determine whether
additional antinociceptive effects of PAP are attributable to inhi-
bition or modulation of other PIP2-sensitive channels, proteins,
or mechanisms.
PIP2 levels at the time of pronociceptive receptor activation
enduringly regulate the magnitude of pain sensitization
We unexpectedly found that nociceptive sensitization could be
enduringly altered by manipulating the levels of PIP2 at the time
of stimulation/injury. This suggests that any manipulation, be it
genetic or environmental, which alters PIP2 levels could have a
lasting impact on nociceptive sensitization. Indeed, we found
that thermal hyperalgesia and mechanical allodynia were endur-
Figure 8. Increasing PIP2 levels at the time of LPA injection or inflammation enhances sen-
sitization. A–D, One hindpaw of WT mice was tested for noxious thermal and mechanical
sensitivity (n  10 mice per group). After taking baseline (BL) measurements, mice were
injected intrathecally with LPA (5 nmol) plus Car or LPA (5 nmol) plus PIP2 (3 nmol) plus Car (A,
B); Car or PIP2 (3 nmol) plus Car (C, D). E, F, One hindpaw of WT mice was tested for noxious
thermal and mechanical sensitivity (n  10 mice per group). After taking BL measurements,
mice were injected intrathecally with LPA (arrowhead; 5 nmol). Three days later, mice were
injected intrathecally with Car or PIP2 (3 nmol) plus Car (arrow). G, H, The hindpaws of WT mice
were tested for noxious thermal and mechanical sensitivity. After taking BL measurements,
mice were injected intrathecally with Car or PIP2 (3 nmol) plus Car, and then were immediately
injected with CFA into one hindpaw (arrowhead). Two hours after CFA injection, mice were
reinjected intrathecally with Car or PIP2 (3 nmol) plus Car (arrow). Inflamed and noninflamed
(control) hindpaws were tested. For A–F, paired t tests were used to compare groups at each
time point. For G and H, paired t tests were used to compare responses at each time point
between mice injected with Car (open circles; injured paw) and those injected with PIP2 plus Car
(open squares; injured paw). *p  0.05, **p  0.005, ***p  0.0005. All data are presented
as means  SEM.
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ingly enhanced only when PIP2 levels were elevated coincident
with LPA receptor activation. PIP2 injection alone or PIP2 injec-
tion several days after LPA injection did not produce, enhance, or
prevent sensitization. Direct elevation of PIP2 in DRGs also
enhanced sensitization caused by peripheral injection of CFA,
further supporting the physiological importance of PIP2 in noci-
ceptive sensitization. Intriguingly, these findings also hint that
PIP2 levels in DRGs regulate sensitization regardless of whether
pain-producing stimuli are administered centrally (i.e., LPA) or
peripherally (i.e., CFA).
Likewise, we found that sensitization could be enduringly al-
tered by increasing or decreasing PIP2 levels through manipula-
tion of PAP activity. Pap/ mice have elevated PIP2 levels in
DRGs and enhanced LPA-, ATP-, CFA-, and nerve injury-
induced nociceptive sensitization [data above and in the study by
Zylka et al. (2008)]. Conversely, S-hPAP injections reduced PIP2
levels in DRGs and enduringly inhibited LPA-, ATP-, CFA-, and
nerve injury-induced nociceptive sensitization. S-hPAP acted ex-
clusively through A1R to mediate these enduring effects (supple-
mental Fig. S6, available at www.jneurosci.org as supplemental
material), ruling out the possibility that PAP acted through other
adenosine receptor subtypes, including A2A (Loram et al., 2009).
Importantly, these alterations in nociceptive sensitization out-
lasted the 3 d antinociceptive effects of S-hPAP and the acute (2
h) elevation of PIP2, arguing that neither maintained activity of
PAP nor long-term elevations of PIP2 contributed to these endur-
ing effects. Instead, these long-term changes in nociceptive
sensitization could be attributable to reduced or enhanced en-
gagement of transcriptional and nontranscriptional mechanisms
that are downstream of pronociceptive receptor/PLC stimulation
(Ji et al., 2009).
Intrathecal injections target DRGs and spinal cord (Luo et al.,
2005). This raises the question of precisely where S-hPAP and
PIP2 act to regulate nociception. Since S-hPAP (intrathecally)
regulates PIP2 levels and nociception through A1R (data above)
(Zylka et al., 2008), S-hPAP has the potential to act on any cell
that expresses A1R. This includes peptidergic and nonpeptidergic
nociceptive neurons as well as postsynaptic neurons in the spinal
cord (Reppert et al., 1991; Li and Perl, 1994; Lao et al., 2001;
Schulte et al., 2003) but excludes microglial cells because they do
not express A1R (Orr et al., 2009). Despite repeated attempts, we
were unable to determine at a cellular level which DRG neurons
incorporated PIP2 (by studying the distribution of PIP2 conju-
gated to fluorochromes) (data not shown). However, nocicep-
tion was only affected over the time period in which PIP2 levels
were elevated in DRGs, arguing that nociceptive neurons in
DRGs were targeted. Furthermore, the elevated levels of PIP2 in
DRGs from Pap/ mice are likely to be restricted to the subset of
peptidergic and nonpeptidergic nociceptive neurons that nor-
mally express PAP (Zylka et al., 2008). We cannot further pin-
point at the cellular level where S-hPAP and PIP2 act to regulate
nociception with existing technologies.
Last, PIP2 levels can be increased or decreased relative to an
intermediate level in DRGs (Fig. 3A,D), suggesting nociception
may be influenced by an underlying “phosphoinositide tone.”
This tone may be coordinated with the “adenosine tone” that is
present in diverse tissues, including the nervous system (Boison,
2008). Our data indicate that adenosine-generating ectonucleoti-
dases like PAP contribute to this underlying phosphoinositide
tone both positively and negatively. It may thus be possible to
harness any molecule or mechanism that causes a sustained re-
duction in this tone to enduringly prevent or treat symptoms
associated with chronic pain.
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